Theranostics continue to gain momentum
advertisement
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

More Magazine Features

The ever-evolving CT tube market Whether OEM or third-party: when it comes to tubes the customer is king

A look back at the remarkable career of Ed Sloan Sr. Celebrating the life and career of the original parts vendor

The value of ISOs in an era of personalization and consolidation The unique value proposition of high quality third-party service

What to look for in an OEM service contract Communication the unique needs of your facility is key to getting the right coverage

The road ahead for breast density awareness It's been a good year for advocacy, here's what happens next

See All Magazine Features  

Molecular Imaging Homepage

First scan in US performed with uEXPLORER Total-Body PET/CT Can scan an entire patient within 15 to 30 seconds

FDG PET better for measuring Alzheimer's cognitive function than amyloid PET (FDG) PET measures brain glucose consumption

PSMA PET/CT may beat Axumin for locating recurring prostate cancer, says study Researchers at UCLA compare imaging approaches

Progenics collabs with VA on AI research for prostate cancer treatment Apply machine learning to medical images

NNSA awards agreements to US firms for Mo-99 production Will produce with no highly-enriched uranium

ANSTO to hike nuclear medicine prices by as much as nine percent Follows Mo-99 leak

New bill calls for changing reimbursement for radiopharmaceuticals Aims for greater patient access to nuclear medicine exams

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million Will gain rights over Axumin

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

Siemens showcases works in progress at SNMMI Includes TeamPlay, syngo Virtual Cockpit and a number of AI algorithms

Theranostics continue to gain momentum

par John R. Fischer , Staff Reporter
From the June 2019 issue of DOTmed HealthCare Business News magazine

In more ways than one, 2018 was a year of expansion for Novartis International. In January the company completed its $3.9 billion acquisition of nuclear medicine company Advanced Accelerator Applications (AAA), and in October it completed the $2.1 billion purchase of biopharmaceutical enterprise, Endocyte.

But in addition to scaling its company footprint, the Swiss-based pharmaceutical provider expanded its stake in another area — the emerging and promising field of theranostics. With AAA providing it access to its neuroendocrine tumor treatment, 177-Lu-Lutathera, and Endocyte giving it the same for its prostate cancer drug, 177-Lu-PSMA-617.

Story Continues Below Advertisement

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.



Interest in theranostics has driven a lot of business activity in recent years and energized not just companies but providers in nuclear medicine in working to develop radiotherapeutic molecules that can diagnose, determine a personalized course of action for, and treat various forms of cancer. The word itself is a portmanteau of diagnostics and therapeutics.

“The strong growth of radiotherapeutics represented around 14 percent of the total nuclear medicine market in 2018 - up from 3 percent in 2012 – and is expected to represent 60 percent, or even more, of the $26 billion U.S. nuclear medicine market by 2030,” Paul-Emmanuel Goethals, co-founder of MEDraysintell, a business intelligence firm specializing in nuclear medicine, told HCB News. “They are driving the growth of radiotheranostics, and their overall development along with that of conventional therapeutics will boost development of associated PET and SPECT tracers.”

Origins, and where it is today
Although the term was first coined in the 1990s, the concept of theranostics dates back to the 1940s when iodine was applied in both diagnostic imaging and therapy for benign and malignant thyroid tumors.

“You can give someone I-123, and using molecular imaging, you can see where the iodine goes and visualize metastatic thyroid cancer,” said Dr. Thomas Hope, a nuclear medicine physician and associate professor of radiology at the University of California, San Francisco. “Then, you can give them I-131, which has a different type of radiation emitted that can treat the thyroid cancer.”

This practice refers to a specific example of theranostics known as radiotheranostics. While in this scenario the same radionuclide is used for diagnosis and therapy, other forms of radiotheranostics involve different radionuclides paired together with a targeting ligand. One radionuclide is used to image the tumor, while the other is used to treat it.
  Pages: 1 - 2 - 3 - 4 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment